Key Takeaways

  • Stellest 2.0 lenses showed 6-month treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation versus single-vision lenses in an ongoing trial in China
  • More than 90% of children in both groups reportedly wore their spectacles for more than 12 hours daily, and 98% fully adapted within 1 week
  • The study remains ongoing, with the prespecified 1-year analysis serving as the primary efficacy endpoint

EssilorLuxottica has announced 6-month interim results from an ongoing randomized, double-masked clinical trial in China evaluating Essilor Stellest 2.0 spectacle lenses for myopia management in children.

At 6 months, Stellest 2.0 lenses demonstrated treatment effects of 0.51 D for myopia progression and 0.21 mm for axial elongation compared with single-vision spectacle lenses, according to the company. EssilorLuxottica said the effects were comparable to those previously reported after 12 months with first-generation Stellest lenses, suggesting a potentially faster treatment response with the newer lens design.

“We are excited by these 6-month interim findings for Essilor Stellest 2.0 lenses, which represent an important milestone in our long-term commitment to advancing myopia management through continuous innovation and clinical research,” Davide Schinetti, chief operating and R&D officer at EssilorLuxottica, said in a statement. “The magnitude and speed of the treatment response observed at 6 months are very encouraging and have not been previously observed across our Stellest clinical research ever."

Stellest 2.0 lenses incorporate H.A.L.T. Max technology. According to EssilorLuxottica, mean myopia progression remained close to 0 D after 6 months in the treatment group.

The interim findings were first presented during an EssilorLuxottica satellite symposium at the World Society of Paediatric Ophthalmology and Strabismus Subspecialty Day, held during the European Society of Cataract and Refractive Surgeons Congress in London.

In addition to the reported effects on myopia progression and axial elongation, the interim analysis showed high spectacle-wearing compliance. More than 90% of children in both study groups wore their spectacles for more than 12 hours per day, 7 days per week, according to the company.

Adaptation was also similar to that observed with single-vision lenses, with 98% of participating children fully adapting to their spectacles within 1 week. The trial is continuing to assess longer-term efficacy and safety. A prespecified 1-year analysis will serve as the study’s primary efficacy endpoint.

The China trial provides the first randomized, double-masked clinical evidence for Stellest 2.0 lenses from the country. EssilorLuxottica said the findings are consistent with results from a randomized contralateral crossover clinical trial conducted in Singapore and published in Translational Vision Science & Technology in 2025.